Ernexa Therapeutics Inc.
ERNA
Last
$2.47
Day
-0.8%
1y
-92.6%
5y
-99.9%
52w
-96.5%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0627d
EMA 21
3.22
EMA 50
3.98
EMA 200
17.39
20d high
-47.0%
5y high
-99.9%
5y range
0th
Positions held
Your positionsERNA isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$3.21
Stop
$1.89
Stop distance
23.5%
Target vs last
+30.0%
Fundamentals
| Market cap | $4.06M | Enterprise value | -$613,296 | Trailing P/E | — | Forward P/E | -0.26 |
| PEG | — | Price / book | 0.91 | Beta | 2.65 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -3.2% | ROA | -105.6% | Debt / equity | 0.11 |
| Current ratio | 2.01 | Free cash flow | -$5.93M | Analyst recommendation | none | Mean target | $30.00 |
| 52w high | $71.50 | 52w low | $2.14 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$4.0M | -$5.5M | -$1.5M | -$1.2M | -$3.1M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Operating income | -$4.1M | -$3.5M | -$2.1M | -$2.0M | -$2.5M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.6M | $0.1M | $0.0M | — |
| Op margin | — | -2963.9% | -30404.4% | — | — |
| Net income | -$14.1M | -$44.5M | -$21.7M | -$24.6M | — |
| Gross margin | — | 83.5% | -247.1% | — | — |
| Gross profit | $0.0M | $0.5M | -$0.2M | $0.0M | — |
| Operating income | -$9.3M | -$17.3M | -$20.7M | -$26.9M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-14 · Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-27 · Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
2026-07-15 · Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)
2026-07-15 · Ernexa Therapeutics Says Preclinical Data Shows Anti-Tumor Activity of ERNA-101 Combination
Price (daily)
Full chart · RSI · MACD · patternsERNA · daily-34.5% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin